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Summary 9 
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The effects of the HIV epidemic, particularly in Southern Africa, have been increasingly 11 
experienced by companies in recent years.  Initially, the lag in presentation of morbidity and 12 
mortality allowed companies to ignore the epidemic.  However, in the past decade, companies 13 
have been confronted with the cost impacts of seriously ill and dying employees.   14 
 15 
Companies in many countries in the region are strongly engaged in generating effective 16 
prevention and treatment and care responses to the epidemic.  However, many small and medium 17 
companies ignore the problem, due to inadequate resources. Nonetheless, some large companies 18 
are pioneering best practices in workplace HIV/AIDS programmes in prevention and care and 19 
treatment. 20 
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Introduction   31 
 32 
In this review we examine the impacts on, and responses of private sector companies to the 33 
HIV/AIDS epidemic in Sub-Saharan Africa particularly Southern Africa. Southern Africa has the 34 
worst HIV epidemic in Africa in terms of morbidity and mortality; it also has some of the best 35 
and most innovative responses by companies.  36 
 37 
Background of HIV/AIDS in Sub-Saharan and Southern Africa 38 
 39 
The increase in mortality due to AIDS has already had a significant demographic effect.  40 
Individuals and households face increasing risks, both directly through the risk of infection and 41 
indirectly as social insurance mechanisms are eroded.  The mortality and morbidity associated 42 
with AIDS are different from any other type of sickness and disease. Whereas most diseases prey 43 
largely on children or the elderly, HIV is transmitted mainly through sexual intercourse which 44 
makes young sexually active adults the most vulnerable.  The majority of PLWHAs are aged 45 
between 19 and 45 (economic prime) and are the primary breadwinners of their families.   46 
 47 
Sub-Saharan Africa is by far the worst affected region in the world by HIV/AIDS [1]. Despite 48 
having just 10% of the global population, it has 66% of People Living with HIV/AIDS 49 
(PLWHAs) and experienced 72% of AIDS deaths in 2007.  It was estimated that about 5% of 50 
adults in the region were PLWHAs at the end of 2007, compared with a global prevalence rate of 51 
less than 1%.  Table 1 summarises the latest available UNAIDS estimates of the numbers of 52 
PLWHAs and AIDS-related deaths in selected countries.   53 
 54 
Southern Africa accounts for 35% of all PLWHAs and almost one third (32%) of all new HIV 55 
infections and AIDS deaths globally in 2007. [1] 
1
 South Africa has an estimated 5.7 million 56 
PLWHAs at end 2007 (UNAIDS 2008). [1] The epidemic is occurring in the most economically 57 
developed part of Africa with South Africa alone accounting for one third of Sub-Saharan Africa 58 
gross domestic product (GDP).   59 
 60 
The increase in mortality due to AIDS has already had a significant demographic effect.  61 
Individuals and households face increasing risks, both directly through the risk of infection and 62 
indirectly as social insurance mechanisms are eroded.  The mortality and morbidity associated 63 
with AIDS are different from any other type of sickness and disease. Whereas most diseases prey 64 
largely on children or the elderly, HIV is transmitted mainly through sexual intercourse which 65 
makes young sexually active adults the most vulnerable.  The majority of PLWHAs are aged 66 
between 19 and 45 (economic prime) and are the primary breadwinners of their families.  [2] 67 
 68 
Table 1:   Key Demographic Indicators of the HIV/AIDS Epidemic Prevalence and Deaths 69 
for Selected Developing Countries in Sub-Saharan Africa – 2007 [1] 70 
 71 
Region and 
Country 
Adults 
(15+) 
HIV prevalence 
among adults (%) 
All AIDS deaths   
Global Total 30,800,000 0.8 2,000,000 
Sub-Saharan 
Africa 
 
20,300,000 
 
5.7 
 
1,500,000 
 3 
Botswana 280,000 26.5 11,000 
Kenya 1,600,000 8.6 108,000 
Malawi 840,000 13.3 68,000 
Mozambique 1,400,000 10.3 81,000 
Namibia 180,000 14.6 5,000 
Nigeria 2,400,000 3.2 17,000 
South Africa 5,700,000 16.9 350,000 
Tanzania 1,300,000 7.0 96,000 
Uganda 810,000 7.9 77,000 
Zambia 980,000 15.4 56,000 
Zimbabwe 1,200,000 26.0 140,000 
  72 
Method - The Costs of HIV/AIDS to a Company 73 
 74 
There is a growing body of evidence from recent research [2,3] that the HIV/AIDS epidemic is 75 
having profound and wide ranging financial impacts on businesses in South Africa. However, 76 
this data comes from relatively few and intensive case studies and many business leaders, even in 77 
high prevalence sectors of the economy, are often unable to point out current and specific 78 
impacts of the epidemic on their operating costs and revenue. 79 
 80 
The individual costs of having one employee with HIV/AIDS are composed of direct or out of 81 
pocket costs and indirect or productivity linked costs.  The direct costs include increased medical 82 
costs and the costs of recruiting and training replacement employees.  The indirect costs include 83 
the reduced productivity of the ill employee, their increased leave and absentee days, increased 84 
supervisor’s time in managing the ill employee, the costs to production until a replacement is 85 
hired and initially lower productivity of that new employee. [2] 86 
 87 
The organisational costs of many employees being ill with HIV/AIDS are also composed of 88 
direct or out of pocket costs and indirect or productivity linked costs.  The direct costs include 89 
increased benefits premiums especially for health insurance, increased number of workplace 90 
accidents and increased legal costs.  The indirect costs include increased senior management 91 
time to deal with HIV/AIDS related matters, disruption to production and loss of workforce 92 
morale, cohesion and experience. [2] 93 
 94 
Figure 1 summarises these costs.  This way of estimating costs, (and that in Figure 2), were 95 
developed in the late 1990’s and applied in a number of studies. They remain as applicable 96 
today.  97 
 98 
Figure 1:  Costs of HIV/AIDS in the workforce [2] 99 
 100 
 101 
 102 
 103 
 104 
Direct (out of pocket) costs Indirect (productivity) costs 
From one employee 
with HIV/AIDS 
(individual costs) 
 Benefits payments 
 Medical care 
 Recruitment and training of 
a replacement employee 
 Reduced on-the-job productivity 
 Increased leave and absenteeism 
 Supervisor’s time 
 Vacancy until replacement is hired 
 Poorer performance while new 
employee learns the job 
From many employees 
with HIV/AIDS 
 Benefits premiums 
 Accidents 
 Senior management time 
 Production disruptions 
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Direct costs are out of pocket expenses for a company that will show up on the company’s 112 
income statement.  Indirect costs are reductions in labour productivity.  Few studies exist which 113 
make some estimates of AIDS-related increases in absenteeism [4,5] and reduction in labour 114 
productivity [6]. This latter study estimated the impact of HIV/AIDS on individual labour 115 
productivity during disease progression and found that the daily difference in tea leaves picked 116 
by a Kenyan tea plucker with AIDS in the last three months of his or her life and a healthy 117 
worker was significantly less. The study not only managed to quantify what AIDS is costing the 118 
Rift Valley tea estates in lost productivity but also gave employers involved in similar labour 119 
intensive agricultural ventures, an idea of how the epidemic could affect them economically. 120 
 121 
Hardest of all to quantify are the indirect costs resulting from multiple cases of HIV/AIDS.  These 122 
impacts include: diminishing employee morale, the disruption of established work teams, the reduced 123 
efficiency of a workforce that has less experience and probably less skill, an increase in labour 124 
disputes as benefits and job security come under pressure, and the burden imposed on managers who 125 
must cope with high workforce morbidity and mortality.  Most of these costs are hidden, and in some 126 
cases they will not become evident until the epidemic is further advanced.   127 
 128 
Timing of the Costs 129 
 130 
Figure 2 illustrates the timing of costs and liabilities which initially are very low or non-131 
distinguishable from normal employee costs.  As the employee progresses into AIDS then these 132 
costs increase, culminating in large termination related and replacement costs. As the epidemic 133 
matures so the costs for the companies increase. Those companies faced with a significant 134 
prevalence rate often respond in various ways which does have a cost implication attached to 135 
those actions.   136 
The progression and intensity of opportunistic infections associated with HIV varies by 137 
asymptotic individual.  For many PLWHA these infections can appear anytime up to 6-8 years 138 
after infection.  Initially the costs and liabilities associated with HIV/AIDS are very low or non-139 
distinguishable from normal employee costs.  As the employee progresses into AIDS then these 140 
costs increase, culminating in large termination related and replacement costs. As the epidemic 141 
matures so the costs for the companies increase. Those companies faced with a significant 142 
prevalence rate often respond in various ways which have a cost implication attached to those 143 
actions.   144 
 145 
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Figure 2:  Progression of cases, costs, and liability [2] 147 
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 152 
 153 
 154 
 155 
Results - Cost Estimates 156 
 157 
There is now a largea growing body of evidence from a decade of intensive work on estimating 158 
the costs of HIV to companies [7-14]. However, not a lot of this work is available in the public 159 
domain as cost impact studies are often done by private consultants and the results held by the 160 
commissioning company. However, a recent review of these estimates found that with few 161 
exceptions the annual labour costs of HIV morbidity and mortality rarely exceeded 3% of payroll 162 
[8] thereby indicating why may companies ignore the effects of HIV/AIDS.  The costs of an 163 
AIDS death or retirement depends upon the skill and productivity level of the employee and 164 
hence their salary level.  In the review it was found that the average costs per AIDS related 165 
termination as a multiple of annual compensation (wages and other benefits) varied between 0.9 166 
and 4.7 percent [8].  One AIDS related death has a severe cost impact whilst simultaneously the 167 
overall cost burden is relatively light. 168 
Progression of 
HIV/AIDS 
in the Workforce 
Cost to Company 
Sickness begins (some 
early deaths, some long-
term survivors) 
Employee becomes 
infected with HIV virus 
Employee leaves 
workforce due to death 
or retirement (some 
long-term survivors) 
Company hires 
replacement employee 
(some employees not 
replaced) 
No cost to company 
Illness-related costs incurred 
(absenteeism, productivity, 
management time, medical care 
and insurance) 
 
 Termination-related costs 
incurred (payouts from retirement 
fund, funeral expenses, loss of 
morale, experience, and 
cohesion) 
 
Turnover costs incurred  
(vacancy, recruiting, training, 
reduced productivity) 
 
Timeline 
(approx) 
Year 0 
Year 1-8 
Year 7-12 
Year 7-12 
Liability Acquired 
by Company 
Present value of all 
costs from years 0-
12 
Employee remains well 
and fully productive 
No cost to company 
Year 0-8 
Maturation of 
epidemic 
Frequent  turnover of 
staff due to AIDS 
illness and death 
HR related costs incurred (Establishment of HIV 
plan/personnel, change in recruitment strategies – 
e.g. employing older women/men, outsourcing, 
shift to capital intensive work)  
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 169 
However, the HIV epidemic has become a major threat to employment objectives and labour 170 
market efficiency [15].   The loss of workers and workdays due to AIDS-related illness or the 171 
demand for caring can result in a significant decline in productivity. Moreover, this leads to a 172 
loss of earnings and attrition in skilled and experienced workers. The obvious effect on the 173 
labour force is a reduction in the number of people of working age. 174 
 175 
AIDS deaths lead directly to a reduction in size of the labour force [9].  The deaths due to AIDS 176 
occur to workers in their most productive years. In 1999, 80% of the new infections were aged 177 
between 20 and 49.  As younger, less experienced workers replace these experienced workers, 178 
labour productivity is reduced.  For example, a Kenyan sugar estate estimates a 50% decrease in 179 
production, as most of the experienced workers died of AIDS related illnesses between 1993 and 180 
1997 [10]. The health cost increased tenfold and funeral costs five times.  Shortages of workers 181 
lead to higher wages, which lead to higher production costs which erodes international 182 
competitiveness and exports.   183 
 184 
In Southern Africa the projected decrease in the labour force participation is 19% for men and 185 
18% for women.  South Africa is losing an annual estimated R12 billion (US$1.2 billion) due to 186 
absenteeism, of which approximately R2 billion (US$200 million) can be attributed to the effects 187 
of HIV/AIDS [11].  The absenteeism rate for PLWHAs was three times higher than others.  188 
PLWHAs were absent 32 days a year on average [11]. 189 
 190 
Company Responses 191 
  192 
Company responses to HIV/AIDS among employees can be summarised under two categories: 193 
prevention and treatment and care.  Individual company treatment responses have been slow 194 
until recently when treatment costs reduced substantially.  As more (mainly larger) companies 195 
have recognised the problems and commenced activities to prevent transmission and treat their 196 
ill employees, a more coordinated approach has emerged in the forms of business coalitions 197 
against HIV/AIDS [101-10444-47]. 198 
 199 
Typically, companies have two objectives in undertaking a workplace HIV/AIDS program: (i) to 200 
limit the incidence of new infections among staff and the surrounding community and (ii) to 201 
manage the impact of existing infections on the company, staff and community. To achieve these 202 
objectives a company's programme might set goals in two areas: (i) changing behavior and 203 
increasing the use of preventative measures and (ii) improving medical care and support to 204 
PLWHAs.  In some cases, companies aim to raise its corporate responsibility profile in the area 205 
of HIV/AIDS by choosing to take a leadership role in mobilising the business community, 206 
getting involved in advocacy at a regional or national level, or supporting social programmes [16-207 
18].   208 
 209 
There are regional differences in the response of business to HIV/AIDS.  Companies with 210 
operations only in America and Europe are less likely to have workplace programmes where 211 
health insurance covers the costs of treating HIV/AIDS.  Companies with African operations are 212 
more likely to implement workplace HIV/AIDS programmes.  More than 70% of multinational 213 
companies surveyed with operations in Africa are now fully subsidizing access to HIV treatment 214 
 7 
for all employees.[19]. Some African companies also provide confidential testing services and 215 
access to treatment for registered or legal dependants although most indigenous companies have 216 
been very slow to offer treatment to their AIDS ill employees [19].   217 
 218 
South African-based companies lead the way internationally in the response to HIV/AIDS.  219 
However, provincial variation can be found with companies in provinces. Companies in Gauteng 220 
province, the economic powerhouse of South Africa, (adult prevalence 21%) and KwaZulu Natal 221 
(28%) are more likely to have implemented programmes than lower prevalence provinces like 222 
the Eastern Cape (19%) and the Western Cape (8%) [1, 13].   223 
 224 
The South African Business Coalition on HIV/AIDS (SABCOHA)  is working with a number of 225 
organisations including Eskom Holdings Limited, Daimler Chrysler, the International Labour 226 
Organisation (ILO) Project (involving Volkswagen's eight supplier companies as part of a 227 
broader ILO Pilot Project), and the Japan Bank for International Co-operation (JBIC), to address 228 
this issue. In June 2008, SABCOHA began to offer supply, or vendor chain, companies the 229 
opportunity to provide free VCT and treatment to their employees as part of a comprehensive 230 
workplace programme [44101].  231 
 232 
Small and micro enterprises (SMEs) are not responding as well to the threat of HIV/AIDS [20].  233 
In South Africa, medium and large companies employ 26% of the working population.  SMEs 234 
provide more than 55% of total jobs, and account for 22% of GDP.  Yet only about 25% of 235 
SMEs are estimated to have established any workplace programmes [21].   This is despite the fact 236 
that potentially, HIV/AIDS could have a more significant impact on SMEs - losing a worker in a 237 
SME can represent a significant proportion of the workforce leading to a reduction in 238 
productivity and high cost of retraining workers, especially skilled staff but they provide fewer 239 
benefits to employees.  SMEs also lack dedicated Human Resource management staff and/or 240 
systems to assess, monitor and devise HIV/AIDS workplace programmes [21, 22].  241 
The matrixTable 2 below offers insight into the impact of and response to HIV/AIDS by 242 
companies according to company size. The impacts and responses have been ranked in order of 243 
importance of HIV/AIDS-related costs taken from a study [23] of South African businesses in 244 
2004. Based on a number of South African studies [3, 12, 13, 24, 25, 26] and a global review [27] of 245 
business perceptions of the epidemic covering the opinions of 10,993 business executives in 117 246 
countries suggests the most common responses. There are exceptions to this norm as there are 247 
small and medium size companies who do provide VCT and treatment. Conversely there are 248 
larger corporate who do not provide the basic of prevention programmes. The construction sector 249 
within South Africa has been critisisedcriticised for their lack of engagement to HIV/AIDS 250 
impact mitigation activities.  251 
Table 2:   Impacts and Responses of Companies by Number of Employees 252 
Company 
Size 
<100 employees 100-500 employees > 500 employees 
Ordered 
Impact and 
Response 
Impact Response Impact Response Impact Response 
1 
Lower 
productivity 
and 
HIV/AIDS 
policy 
Lower 
productivity 
and increased 
HIV/AIDS 
policy 
Higher 
employee 
benefit costs  
HIV/AIDS 
policy 
 8 
increased 
absenteeism  
absenteeism  
2 
Loss of 
experience 
and vital 
skills  
Some 
Education 
and 
Awareness 
activity – 
usually 
taking the 
form of 
posters 
and 
condom 
distribution 
Higher 
employee 
benefit costs  
Some 
Education 
and 
Awareness 
activity – 
usually 
taking the 
form of 
posters 
and 
condom 
distribution 
Intervention 
costs: 
Voluntary 
counselling 
and testing or  
HIV/AIDS  
awareness  
programmes 
Establishment 
of an 
HIV/AIDS 
committee 
and/or 
coordinator 
3 
Higher 
labour 
Turnover 
rates  
 Loss of 
experience 
and vital skills  
 Lower 
productivity 
and increased 
absenteeism 
Education 
and 
Awareness 
activities 
4 
Higher 
employee 
benefit costs 
 Higher labour 
turnover 
rates 
 Intervention 
costs: 
HIV/AIDS 
Treatment 
VCT 
5 
Higher 
recruitment 
and training 
costs 
 Higher 
recruitment 
and training 
costs 
 Intervention 
costs: 
Research into 
the impact of 
HIV/AIDS 
ART provision 
 253 
 254 
 255 
Prevention Activities 256 
 257 
Peer Education 258 
 259 
Studies [28-30] have shown peer education to be one of the most widely-used strategies for 260 
raising awareness of HIV/AIDS. Peer education typically involves training and supporting 261 
employees to affect change among their peers.  Principles and components that affect HIV/AIDS 262 
peer education programme quality and effectiveness include: (i) providing training for peer 263 
educators; (ii) compensating them in some way; (iii) involving them in the design of training 264 
curriculum and materials; and (iv) linking the education programme to other services such as 265 
access to condoms, medical care and voluntary HIV counselling and testing. 266 
 267 
Voluntary HIV Counselling and Testing (VCT) 268 
 269 
Many people are unaware of their HIV status. From a behavior change and treatment 270 
perspective, this knowledge is critical. VCT has proven effective in promoting prevention for 271 
those who test negative and behavior change for those who test positive. 272 
 273 
Although participation in workplace VCT Campaigns is often limited [24], VCT uptake is 274 
increasing over time. When AngloAmerican started their VCT campaign in 2003 they had less 275 
than 10% uptake. In 2005 this increased to 31% and in 2007 it reached 72% [31]. This appears to 276 
be the trend in other companies who have ongoing VCT programmes for a number of years. 277 
There are some ‘best practice’ examples of companies like Shell (Kenya) who have achieved 278 
VCT uptake of in excess of 90% [32].  279 
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 280 
De-stigmatizing the disease  281 
 282 
Discrimination in the workplace reinforces stigmatization of PLWHAs. At the same time, the 283 
workplace offers a unique opportunity to confront societal discrimination and stigma by 284 
dispelling myths and communicating that there is no need to fear PLWHAs. 285 
 286 
These messages can be further reinforced by workplace-based, anti-discrimination policies and 287 
programmes which demonstrate that people can live and work with HIV, often for many years. 288 
Encouraging an HIV/AIDS support group for employees, or involving PLHWAs in company 289 
awareness activities, can also be a powerful means of breaking down misconceptions, fostering 290 
understanding and acceptance, and enabling employees to freely and openly participate in 291 
company treatment programmes [33-34]. 292 
 293 
Treatment and Care Activities 294 
 295 
In some enlightened, but still rare cases, the costs of anti-retroviral treatment (ART) for infected 296 
employees are met by the companies themselves [24, 35-38].    297 
 298 
There is now a discernable shift from orthodox occupational health programmes, to designing 299 
and implementing programmes aimed at treating and managing their infected employees, 300 
especially amongst larger companies. A number of factors have contributed to this situation, 301 
including: 302 
 303 
Maturing epidemic: An increasing number of infected employees are falling ill and employers 304 
are starting to experience the financial effects of the epidemic by way of rising absenteeism and 305 
increasing staff turnover rates.  306 
 307 
Falling costs of treatment: The cost of treating a PLWHA has dropped considerably. In 1998, the 308 
annual cost of treating a PLWHA stood in the region of $US7,000 while in 2008, it was $US250 309 
per annum. This has resulted in companies reassessing the provision of treatment to employees 310 
[39].  311 
 312 
Activist pressure: Civil society, trade unions and NGO’s have lobbied governments to provide 313 
treatment to PLWHA. This coupled with a growing corporate culture of providing treatment, has 314 
resulted in more companies developing programmes to treat their infected employees.  315 
 316 
The majority of countries have implemented national ART programmes which vary in terms of 317 
the extent to which they provide comprehensive treatment and in terms of access, but this move 318 
has prompted companies, in particular multi-nationals to begin forging partnerships with 319 
government. These partnerships often come in the form of cross utilisation of resources. 320 
Examples of these partnerships can be found in Botswana where Debswana Diamond Mines 321 
opens its health facilities to the community whilst in Zambia, Zambian Breweries uses local 322 
clinics and hospitals to treat its staff.   323 
 324 
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Many companies provide ART independently of public health programmes on the grounds that 325 
the costs of not intervening would soon outweigh the costs of treatment. The general rationale is 326 
that ART enables HIV infected employees to remain productive which generates indirect savings 327 
through the saving of recruitment, training and absenteeism costs. In every company, however, 328 
the projected economic returns have yet to be fully achieved due primarily to the slow take-up of 329 
ART amongst employees.  330 
 331 
Recent studies in companies providing ART reveal [21, 24]: 332 
 limited participation of employees in VCT, perceived to be due to persistent fears of 333 
discrimination and stigma in workforces; 334 
 limited numbers of individuals on ART (majority of companies with less than 1% of the 335 
employees on treatment) presenting a very high cost ratio for individual care; 336 
 tendency of PLWHAs to seek treatment once they are very sick and incapable of 337 
working, thereby confounding intentions to maintain worker productivity by enrolling 338 
individuals in health programmes before they fall ill; 339 
 high costs in time and resources expended to enrol employees. 340 
 341 
 342 
Workplace ART programmes and the collaboration and partnerships they entail are an 343 
innovation that can complement government efforts to contain and manage HIV/AIDS 344 
epidemics. An important implication is that if company initiatives are to be effective and 345 
complement government efforts, there needs to be better co-ordination. The notion of 346 
‘partnership’ needs to be developed for the benefit of overall treatment efforts.  347 
 348 
Whilst companies struggle to get HIV infected employees on treatment [34], the benefits are 349 
evident [40] once an employee is successfully placed on a treatment programme. A study at a 350 
Kenyan tea estate has revealed that after 12 months on ART, employees worked at least twice as 351 
many days in the month than they would have in the absence of ART. This study is the first and 352 
only one of its kind and there is a real need for further research in this field.  353 
 354 
Conclusions and Future Perspective 355 
 356 
At the end of 2008 the global economy appeared to be spiraling into recession. The switch from 357 
boom to bust happened in a few short months. In July 2008, oil prices reached an all time high of 358 
$147 per barrel and, most commodity prices were rising rapidly and it seemed that there was 359 
little to worry about in global economic terms. In January 2009 oil had fallen to less than $34 per 360 
barrel [41] and most other commodities had fallen dramatically. In November 2008, the IMF 361 
warned that prospects for global growth had deteriorated and the evidence since then is that the 362 
contraction has continued. The IMF predicted that world output would expand by 2.2% in 2009, 363 
down by some 0.75% of GDP compared to their October forecast. In emerging markets, growth 364 
would 'slow appreciably'[42].   365 
  366 
The consequences of a global recession will be far reaching. Slower growth means fewer jobs 367 
and redundancies. Pressure on the private sector profits will lead to a greater focus on core 368 
business which means that if HIV interventions and AIDS treatment are not seen as crucial then 369 
there may be cut backs. There will also be an impact on international foreign aid. Data show that 370 
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after the 1991 banking crisis in Scandinavia foreign aid flows from Finland, Norway and Sweden 371 
fell and took between 7 and 10 years to recover. Many philanthropic bodies have their resources 372 
invested in the world's stock markets and they may face constraints as returns fall. The point of 373 
this is simply to note that the world has changed and it is crucial that those working in the field 374 
of HIV/AIDS recognise this. 375 
 376 
However, the impact of HIV/AIDS on companies is very real.  Companies in many countries are 377 
now strongly engaged in generating effective prevention and treatment and care responses to the 378 
epidemic.  However, this does vary by company size, with many small and medium companies 379 
continuing to ignore the problem, due to inadequate resources. Whilst some large companies are 380 
pioneering best practices in workplace HIV/AIDS programmes in prevention and care and 381 
treatment. 382 
 383 
Expectantly, those companies whose profitability is more adversely affected have more 384 
motivation to respond; also companies that are more profitable have the financial capacity to 385 
respond. Secondly, those companies who experience more pressure through union and public 386 
opinion are more likely to respond [43]. 387 
 388 
To ensure that the economies within the countries in Southern Africa remain buoyant, there is a 389 
need for companies and government to work together in an effort to manage HIV/AIDS. This 390 
means maximising treatment efforts throughout the economy through the fostering of 391 
partnerships. Whilst managing the health of PLWHAs remains important, it does not hide the 392 
fact that this exercise acts only to mop up an ever increasing flow of new infections. The ultimate 393 
objective remains to halt new infections and this can only be done through successful prevention 394 
and treatment programmes championed by companies.  395 
 396 
There is much work remaining to be done in companies to adequately address the impacts of this 397 
large epidemic. 398 
 399 
 400 
 401 
402 
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Executive Summary 417 
 418 
Scale of the Epidemic 419 
 420 
 The unprecedented scale of the HIV epidemic, particularly in Southern Africa, has meant 421 
that companies have been confronted by many sick and dying employees. 422 
 423 
Cost Impacts on Companies 424 
 425 
 The cost impacts have been increasingly experienced by companies in recent years.  The 426 
lag in presentation of morbidity and mortality allowed companies to initially ignore the 427 
epidemic. 428 
 429 
 The impact of HIV/AIDS on companies is now very real.   430 
 431 
Company Responses 432 
 433 
 Companies in many countries are now strongly engaged in generating effective 434 
prevention and treatment and care responses to the epidemic.   435 
 436 
 However, this does vary by company size, with many small and medium companies 437 
continuing to ignore the problem, due to inadequate resources.  438 
 439 
 Some large companies are pioneering best practices in workplace HIV/AIDS 440 
programmes in prevention and care and treatment. 441 
 442 
 443 
Conclusions 444 
 445 
 Companies until the last decade ignored the increasing level of morbidity and mortality. 446 
 447 
 Evidence on private sector responses shows wide range of responses 448 
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 449 
 Data on private sector responses is limited, as such, there is little comprehensive data on 450 
the costs of HIV on private sector in southern Africa. Lack of information is the reason 451 
for many companies continuing to ignore the epidemic. However, there are companies 452 
which have recognized the threat and in developing workplace programmes; have 453 
become leaders and exemplars of ‘best practice’ 454 
 455 
 The HIV response in the private sector is evolving – early interventions that focused on 456 
education are now incorporated into broader programmes (VCT and provision of ART, 457 
supply chain etc) 458 
 459 
 There is much work remaining to be done in companies to adequately address the impacts 460 
of this large epidemic. 461 
 462 
463 
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